DEVELOPING IMMUNOEPIGENETIC PLATFORMS FOR PERIPHERAL T‐CELL LYMPHOMA: LEVERAGING A LOGIC FOR PD1/PDL‐1 INHIBITORS von O'Connor, O.A.

Volltext

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma von Horwitz, S., O'Connor, O.A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N.L., Christensen, J.H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W.S., Feldman, T., Menne, T., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., Shustov, A., Hüttmann, A., Savage, K.J., Yuen, S., Zinzani, P.L., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M., Illidge, T.

Volltext

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study von Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Nasta, S., O'Connor, O. A., Shi, H., Boral, A. L., Fisher, R. I.

Volltext

Apoptosis: from biology to therapeutic targeting von O'Connor, O.A.

Volltext

ANALYSIS OF PUBLISHED TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY (R/R) PERIPHERAL T–CELL LYMPHOMA (PTCL): AN EVIDENCE BASED DECISION MAKING APPROACH von Marchi, E., Tobinai, K., Maruyama, D., Nagai, H., O'Connor, O.A.

Volltext

SURVIVAL BENEFIT WITH NOVEL AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS (PTCL): THE COLUMBIA UNIVERSITY EXPERIENCE von Ma, H., Marchi, E., Cheng, B., O'Connor, O.A.

Volltext

CASE MATCH CONTROL ANALYSIS OF PROPEL REVEALS A SURVIVAL ADVANTAGE FOR PATIENTS WITH RELAPSED PTCL RECEIVING PRALATREXATE: A NOVEL APPROACH TO BENCHMARK DRUGS IN RARE DISEASES von O'Connor, O.A., Marchi, E., Kim, W.S.

Volltext

UMBRALISIB AND CARFILZOMIB POTENTLY INHIBIT CAP DEPENDENT TRANSLATION IN LYMPHOMA von Pal, I., Sardinha, A.G., Scotto, L., Mundi, P.S., O'Connor, O.A., Deng, C.

Volltext

AZACYTIDINE AND DECITABINE EXHIBIT DIFFERENTIAL EFFECTS ON CYTOTOXICITY AND METHYLATION AND EXHIBIT CLASS SYNERGY WITH HDACI IN MODELS OF PTCL von Scotto, L., Kinahan, C., Casadei, B., O'Connor, O.A.

Volltext

A FIRST‐IN‐HUMAN TRIAL OF THE NOVEL MULTI‐ACTION THERAPY TINOSTAMUSTINE (EDO‐S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) von Pinto, A., De Filippi, R., Zinzani, P., Driessen, C., Tun, H.W., Hilgier, K., Remmy, D., Mehrling, T., O'Connor, O.A.

Volltext

407 POSTER Translational development of the novel kinesin spindle protein (KSP/Eg5) inhibitor SB-743921 (SB-921) in lymphoma: from preclinical models to phase 1 studies von Zain, D, Bongero, D, Goy, A, Orlowski, R, Hainsworth, J, Afanasyev, B, Chen, M.M, Escandon, R, Mao, Y, O'Connor, O.A

Volltext

FIRST‐IN‐CLASS HAT ACTIVATOR HIGHLY SYNERGISTIC WITH PAN‐HDAC INHIBITOR ROMIDEPSIN LEADING TO PROFOUND HISTONE ACETYLATION CYTOTOXICITY von Liu, Y., Fiorito, J., Gonzale, Y., Zuccarello, E., Calcagno, E., Camarillo, J.M., Thomas, P.M., Kelleher, N., Deng, S., Landry, D., O'Connor, O.A., Wolfe, A.J., Moyer, B., Arancio, O., Amengual, J.

Volltext

ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT‐402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA von Radford, J., Kahl, B., Hamadani, M., Carlo‐Stella, C., O'Connor, O.A., Ardeshna, K.M., Feingold, J., He, S., Reid, E., Solh, M., Chung, K., Heffner, L., Ungar, D., Caimi, P.

Volltext

PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY) von Zhu, J., Song, Y., Smith, S.D., O'Connor, O.A., Luo, W., Shazer, R.L., Zhang, L., Han, I., Jivani, M.A., Liu, Y., Nowakowski, G.S.

Volltext

TARGETING THE PERIPHERAL T‐CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5‐AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL‐MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY von Falchi, L., Lue, J.K., Montanari, F., Marchi, E., Amengual, J.E., Sawas, A., Deng, C., Khan, K., Kim, H.A., Rada, A., Malanga, M., Francescone, M.F., Soderquist, C.R., Park, D.C., Bhagat, G., Sokol, L., Shustov, A.R., O'Connor, O.A.

Volltext

RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON‐2 TRIAL von Illidge, T., Horwitz, S., Iyer, S., Bartlett, N., Kim, W., Tilly, H., Belada, D., Feldman, T., Illés, Á., Jacobsen, E., Hüttmann, A., Zinzani, P., O'Connor, O.A., Trepicchio, W., Miao, H., Rao, S., Onsum, M., Manley, T., Advani, R.

Volltext

Effects of sterilization methods on the physical characteristics of soil: implications for sorption isotherm analyses von LOTRARIO, J. B, STUART, B. J, LAM, T, ARANDS, R. R, O'CONNOR, O. A, KOSSON, D. S

Volltext

UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY... von Zinzani, P., Samaniego, F., Jurczak, W., Lech‐Maranda, E., Ghosh, N., Anz, B., Patten, P., Reeves, J., Leslie, L.A., Smolewski, P., Chavez, J.C., Scarfo, L., Derenzini, E., Burke, J.M., Sharman, J., Kolibaba, K., O'Connor, O.A., Cheah, C.Y., Miskin, H.P., Sportelli, P., Weiss, M.S., Fowler, N.H.

Volltext

FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL von Kahl, B., Hamadani, M., Caimi, P.F., Reid, E.G., Havenith, K., He, S., Feingold, J.M., O'Connor, O.A.

Volltext

Analysis of preclinical and clinical samples after treatment with a CD37 targeting antibody drug conjugate (AGS67E) support a high level of CD37 expression in NHL von Doñate, F., Yang, P., Morrison, K., Karki, S., Aviña, H., Lackey, J.M., Sawas, A., Savage, K.J., Perez, R.P., Advani, R.H., Zain, J.M., O'Connor, O.A., Reyno, L.M.

Volltext